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Background: Molecular tests allow the detection of high-risk human papillomavirus in cer-
vical  samples, playing an important role in the prevention of cervical cancer.
Objectives:  We  performed a study to determine the prevalence of HPV 16, HPV 18 and other
high-risk  human papillomavirus (pool 12 genotypes) in Peruvian females from diverse urban
areas  using the cobas 4800 HPV test.
Methods: Routine cervical samples collected in our laboratory were analyzed by cobas 4800
HPV  test.
Results: A total of 2247 samples from female patients aged 17–79 years were tested. high-
risk  human papillomavirus was positive in 775 (34.49%) samples. Of these, 641 (82.71%)
were  single infections and 134 (17.29%) were multiple infections. The positivity rates for
HPV  16, HPV 18, and other high-risk human papillomavirus were 10.77%, 2.0%, and 28.08%,
respectively.  In multiple high-risk human papillomavirus infections, the concomitance of
HPV 16 and other high-risk human papillomavirus was  more prevalent (13.42%).
Conclusion: Our study showed high prevalence of high-risk human papillomavirus in urban
Peru,  mainly among young women. In both single and multiple infections other high-risk
human  papillomavirus were more prevalent than HPV 16 and HPV 18, which might inﬂuencevaccine  impact in our country. Furthermore, the cobas 4800 HPV test may be considered a
useful tool for HPV molecular diagnosis.
© 2014 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDntroduction
ervical cancer is the second most common cause of cancer
n  women1 and it is estimated that each year approximately
93,000 new cases are diagnosed and 274,000 women  die from
ervical  cancer worldwide.2 Human Papillomavirus (HPV) has
een recognized as an important cause of cervical cancer3 and
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in  the world.4 More than 40 HPV genotypes have been detected
in  the anogenital mucosa and are usually transmitted through
sexual  activity.5 The HPV genotypes 16, 18, 31, 33, 35, 39, 45,a 11, Peru.
51,  52, 56, 58, 59, 66, and 68 are associated with cervical cancer
and  have been classiﬁed as high-risk (HR) group.6,7
A global meta-analysis showed that the prevalence of
HPV  in 157,879 women with normal cytology was 10.4%. The
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other  HR-HPV were  the most common (13.42%) coinfections,
while HPV 16 and HPV 18 coinfections were the least common
Table 1 – Prevalence of HR-HPV among 2247 samples.
Result of cobas testing Samples Prevalence (%)
HR-HPVa 775 34.49
Negative 1472 65.51
Total 2247 100.00
a HPV 16, 18 and other HR-HPV (31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
66 and 68).
Table 2 – Frequency of HPV 16, 18 and other HR-HPV.
Outcomes of cobas testing Samples Frequency (%)c
HPV 16a 242 10.77
HPV 18a 45 2.00
Other HR-HPVa,b 631 28.08470  b r a z j i n f e c t d 
prevalence estimates by region were Africa 22.1%, Central
America  and Mexico 20.4%, Northern America 11.3%, Europe
8.1%,  and Asia 8.0%.8 Of all high-risk human papillomavirus
(HR-HPV) genotypes, HPV 16 has been regarded as the most
prevalent  genotypes.9
Few studies have examined the epidemiology of HPV in
Peru.  In the Department of San Martin, 5435 women were
tested  for HPV by Hybrid Capture II (Qiagen, Gaithersburg, MD);
the prevalence of HPV was  estimated to be 12.6%.10 On the
other  hand, the overall presence of HR-HPV was  33.6% in a
study  of 2208 women  with abnormal cytology from different
cities  in Peru.11 Also, an analysis performed on 384 cervical
samples from six regions with the highest percentage of rural
inhabitants  in Peru showed the presence of HPV in 73 cases
(19.01%)  and the most common genotype was  HPV 16, found
in  six (8.22%) cases.12
The DNA testing of HR-HPV genotypes in cervical samples
has  a sensitivity of up to 96.6% for detecting precancerous
lesions.13 The cobas 4800 HPV Test (Roche Molecular Sys-
tems,  Inc) is a qualitative in vitro test for the detection of
HPV  in patient specimens. The test utilizes ampliﬁcation of
target  DNA by real time PCR and nucleic acid hybridization
for the detection of 14 HR-HPV genotypes in a single analy-
sis.  The test speciﬁcally identiﬁes genotypes 16 and 18 while
simultaneously detecting the other HR genotypes (pool of 12
genotypes:  31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). The
ATHENA  (Addressing THE Need for Advanced HPV Diagnos-
tics)  study, involving more  than 47,000 women in the United
States,  demonstrated that the cobas 4800 HPV Test is clinically
validated  for ASCUS triage.14
The present study aims to determine the prevalence of HPV
16,  HPV 18 and other HR-HPV (pool of 12 genotypes) in cervical
scrapes  from women  living in diverse urban areas in Peru by
the  cobas 4800 HPV Test.
Materials  and  methods
Study  population
During the period from November 2011 to October 2013, rou-
tine  cervical samples collected from women living in different
urban  areas across the country were  received at the laboratory.
Urban  areas include the cities of Iquitos, Cajamarca, Piura,
Chiclayo,  Lima, Arequipa, Cuzco and Juliaca. On date of arrival,
the  samples were  registered and labeled with a barcode for
personal  identiﬁcation.
Cobas  4800  HPV  test
The cobas 4800 HPV test is a qualitative assay for the presence
of  HPV 16, HPV 18 and a pool of 12 other HR-HPV genotypes
(31,  33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). This test requires
1  mL  of liquid cytology sample. No pre-treatment of samples
is  required. The cobas 4800 HPV test was  performed according
15to  the recommendations of the manufacturer. Brieﬂy, DNA
was  extracted, puriﬁed and prepared for PCR by the cobas x 480
instrument. Ampliﬁcation and detection of HR-HPV DNA were
undertaken  on the cobas z 480 analyzer. Fluorescent TaqMan 1 4;1  8(5):469–472
probes  were  used for detection of the amplicons during PCR
cycles.
Both  positive and negative control specimens are included
in  each run. In addition, the test detects beta-globin DNA as
an  internal control of sufﬁcient specimen cellularity. Special-
ized  pipetting technology combined with AmpErase enzymes
reduces  cross contamination risk.
Analysis
HPV detection in cervical samples was  considered as posi-
tive  or negative. Prevalence of HPV including HPV 16, HPV 18
and  other HR-HPV (pool of 12 genotypes) was  reported. The
frequencies of single and multiple HPV infections were  also
described.  The results of the cobas testing were  tabulated by
age  of the female patients.
Results
A total of 2247 cervical samples were analyzed. Patients were
with  the age 17–79 years (average 34.48 years). All cervical
samples contained sufﬁcient DNA to perform PCR, based on
ampliﬁcation  of the human beta-globin gene. In the present
study,  HR-HPV was detected in 775 samples and the over-
all  prevalence was  34.49% (Table 1). HPV 16 was  detected in
242  samples, HPV 18 in 45 samples, and other HR-HPV (pool
of  12 genotypes) in 631 samples, either as single or multiple
infections combined (Table 2). The prevalence of other HR-HPV
(28.08%)  was higher than HPV 16 (10.77%) and HPV 18 (2.0%).
Of  775 HPV positive samples, 641 (82.71%) were  single
infections and 134 (17.29%) were  multiple infections. Other
HR-HPV  (pool of 12 genotypes) were the most common in
single  (500/641) and in multiple infections (131/134). In single
infections,  HPV 16 was  detected in 126 samples, whereas HPV
18  in 15. With respect to multiple HPV infections, HPV 16 anda Single and multiple infections combined.
b Genotypes 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
c HPV positive in the total of samples.
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Table 3 – Single or multiple infections in 775 HPV positive samples.
Genotype Single infections Relationship Multiple infections
n %b n %b
HPV 16 126 16.26 HPV  16/HPV 18 3 0.39
HPV 18 15 1.93 HPV 16/other HR-HPVa 104 13.42
Other HR-HPVa 500 64.52 HPV 18/other HR-HPVa 18 2.32
– – – HPV16/HPV18/other HR-HPVa 9 1.16
Total 641 82.71 Total 134 17.29
a Genotypes 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
b Frequency: n among total HPV positive samples.
Table 4 – HR-HPV detection according to age.
Age (years) HR-HPVa Prevalence (%)
17–29 334 43.10
30–39  290 37.42
40–49  108 13.93
50–59  34 4.39
60–79 9 1.16
Total 775 100.00
a
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1. Pisani P, Bray F, Parkin DM. Estimates of the world-wide
prevalence of cancer for 25 sites in the adult population. Int JHPV 16, 18 and other HR-HPV (31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
66 and 68).
0.39%). Also we  observed the simultaneous presence of HPV
6,  HPV 18 and other HR-HPV at least in nine samples (Table 3).
The  prevalence of HR-HPV was  highest in younger women
nd  showed a decreasing trend with age (Table 4). The preva-
ence  according to age was  as follows: 43.1% for women under
9  years; 37.42% for those between 30 and 39 years; 13.94%
n  the age range 40–49; 4.39% between 50 and 59; and 1.16%
mong  those aged 60–79.
iscussion
he high prevalence of HR-HPV (34.49%) in women from dif-
erent  urban areas of Peru is similar to that described in other
ountries  such as Russia, 29.1%; Trinidad and Tobago, 35.4%;
nd  East African countries, 33.6%.8,16 But it was  higher in other
arts  of Latin America, such as Mexico, 14.5%; Costa Rica,
6.0%;  Colombia, 20.5%; and Ecuador, 24.2%.17–20 However, it
as  lower than the rate found in Brazil (Rio de Janeiro).21 As it
appens  in most developing countries, some socio-economic
nd  cultural factors may  be related to this high HPV preva-
ence,  especially early start of sexual activity; multiparity; lack
f education; and the misconceptions and beliefs that con-
train  people from discussing diseases of the genital tract.22
In Peru, previous studies found that the prevalence of HPV
n  the Department of San Martin was  12.6%10 and in some
ural  areas was  19.01%,12 which were lower than the preva-
ence  obtained in the present study. However, our data are
onsistent  with those obtained by Li Ning et al.,11 where the
revalence  of HR-HPV in different cities of our country was
3.6%.This  is the ﬁrst study about prevalence of HR-HPV using
he  cobas 4800 HPV Test in our country. As a part of our
outine, cervical samples were received for HPV moleculardiagnosis. The test identiﬁes the presence of HPV 16, HPV 18
and  other HR-HPV (pool of 12 genotypes), which are involved
with  cervical cancer.23 In both single and multiple infec-
tions, other HR-HPV were more  common than HPV 16 and
HPV  18, similar to a previous study in 5072 women  from
Denmark.24 This is because infections by other HPV genotypes
(not  16/18) are more  frequent in women with normal cytol-
ogy  or low-grade CIN, although these genotypes only cause
about  one-third of cervical cancer.25 Furthermore, our results
are  in line with studies indicating higher prevalence of HR-HPV
in  young women  (17–29 years) and HPV infection decreasing
with  aging24,26,27 However, it is important to identify which
are  the most common genotypes in the group of other HR-
HPV.  This would help to include the prevailing genotypes in
the  design of multivalent vaccines. It is also desirable to incor-
porate  these genotypes in the next generation of automated
molecular diagnostic systems.
Several studies assessed the use of the cobas 4800 HPV
test.24,28–31 Those studies showed that the test have a high
speciﬁcity and sensitivity, less cross contamination risk, clin-
ical  relevance, sufﬁcient interlaboratory reproducibility, and
less  labor intensive. Additionally, this test fulﬁlls all require-
ments  as deﬁned by the international guidelines32 when
assessing a test for screening purposes.
In conclusion, our study showed a high prevalence of
HR-HPV  in females from diverse urban areas of Peru espe-
cially  among young women. Both single and multiple HR-HPV
infections  underscore the presence of HR-HPV (pool of 12
genotypes)  in excess of HPV 16 and HPV 18. This ﬁnding might
inﬂuence  vaccine impact in our country. Finally, the cobas
4800  HPV Test proved to be a useful tool for HPV molecular
diagnosis.
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